Dianabol and Liothyronine (T3) Interaction: Avoid | Peptide Database

Join others researching Raloxifene — share findings, ask questions, and learn from real experiences Raloxifene is a second-generation selective estrogen receptor modulator (SERM) FDA-approved for the prevention and treatment of postmenopausal osteoporosis and for breast cancer risk reduction. Unlike tamoxifen, raloxifene has a benzothiophene core rather than a triphenylethylene backbone, giving it a distinct tissue-selectivity profile. In performance enhancement contexts, raloxifene is widely regarded as the preferred SERM for gynecomastia reversal because of its stronger antagonist activity at breast tissue estrogen receptors with fewer off-target effects. However, raloxifene is not an effective standalone post-cycle therapy drug because it does not stimulate the hypothalamic-pituitary-testicular axis as robustly as tamoxifen or enclomiphene. Its weaker antagonism at hypothalamic estrogen receptors means it produces comparatively modest elevations in LH and FSH, making it poorly suited for driving testosterone recovery after anabolic steroid cycles. Raloxifene carries a lower risk of endometrial stimulation than tamoxifen, as it acts as an estrogen antagonist rather than a partial agonist in uterine tissue. Raloxifene binds to both estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta), producing tissue-dependent agonist or antagonist effects determined by the local complement of coactivator and corepressor proteins. In breast tissue, raloxifene functions as a potent estrogen antagonist, blocking estradiol-mediated proliferative signaling with high selectivity. This strong breast-tissue antagonism underlies its effectiveness for gynecomastia treatment and breast cancer risk reduction. In bone, raloxifene acts as an estrogen agonist, maintaining bone mineral density by inhibiting osteoclast-mediated resorption. Critically, raloxifene is a weaker antagonist at hypothalamic estrogen receptors compared to tamoxifen, which means it produces less disruption of estrogen-driven negative feedback on GnRH secretion. The result is a more modest increase in LH and FSH compared to tamoxifen, limiting its utility as a standalone PCT agent. In the uterus, raloxifene does not exhibit the partial agonist activity seen with tamoxifen, which translates to a substantially lower risk of endometrial hyperplasia and endometrial cancer with long-term use. Raloxifene is metabolized primarily through glucuronidation rather than CYP450-dependent oxidation, which reduces the potential for drug-drug interactions compared to tamoxifen.

FDA-approved for the treatment of primary hyperlipidemia and mixed dyslipidemia. Pitavastatin 2-4 mg provides clinically meaningful LDL reduction comparable to moderate-intensity atorvastatin or rosuvastatin. Particularly well-suited for patients on complex medication regimens where drug interactions are a concern. Used off-label to manage lipid disturbances caused by anabolic steroid cycles. Its primary advantage in this context is the absence of CYP3A4 interactions, meaning it can be safely co-administered with compounds, ancillaries, and other medications without dose adjustments or concerns about altered statin levels. The relatively stronger HDL-raising effect compared to other statins is an additional benefit given that HDL suppression is often the most resistant lipid abnormality during AAS use. The preferred statin choice for individuals with pre-existing insulin resistance, metabolic syndrome, or borderline glucose tolerance. The J-PREDICT trial showed pitavastatin actually reduced the incidence of new-onset diabetes by 18% compared to placebo, in contrast to other statins which modestly increase diabetes risk. This is particularly relevant for AAS users running compounds that affect glucose metabolism such as growth hormone or certain oral steroids. Appropriate for cardiovascular risk reduction in individuals with dyslipidemia and additional risk factors. While pitavastatin lacks the large-scale dedicated cardiovascular outcomes trial data that rosuvastatin and atorvastatin have (JUPITER, ASCOT), its class-effect benefits are well established and supported by the long-term LIVES study data from Japan. The statin of choice when drug interaction potential must be minimized. Especially relevant for individuals taking azole antifungals, macrolide antibiotics, protease inhibitors, or other CYP3A4 inhibitors that would significantly increase blood levels of atorvastatin or simvastatin. In the AAS context, this is advantageous for users running multiple compounds with hepatic metabolism.